HAIC Combined With Tislelizumab and Apatinib for Unresectable Intrahepatic Cholangiocarcinoma
NCT05290116
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
17
Enrollment
OTHER
Sponsor class
Conditions
Intrahepatic Cholangiocarcinoma
Interventions
DRUG:
HAIC Combined with Tislelizumab and Apatinib
Sponsor
Yunfei Yuan